Search Results Within Category "Heart and Vascular"
Suggestions within category "Heart and Vascular"
Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE)- US Cohort is referred to as the GSR DEFINE- US Cohort study
A PROSPECTIVE, OBSERVATIONAL STUDY THAT WILL DOCUMENT THE LONG-TERM SAFETY, EFFECTIVENESS, AND DURABILITY OF RENAL DENERVATION IN A REAL-WORLD POPULATION, AGED 65 YEARS OR GREATER WITH HYPERTENSION IN THE UNITED STATES.
Sarah Ackroyd - sackroy1@hfhs.org
BradycArdia paCemaKer with AV interval modulation for Blood prEssure treAtmenT (BACKBEAT Trial)
The purpose of this study is to evaluate the effectiveness and safety of a new pacemaker program called Atrioventricular Interval Modulation (AVIM) in patients who are scheduled to have, or recently received, a pacemaker (either the Medtronic Astra model or Medtronic Azure model) to treat hypertension.
Briita Wanhala - bwanhal1@hfhs.org
• Patients with a Dual-chamber Medtronic pacemaker
• Patients that have Hypertension
• Patients currently taking at least 1 antihypertensive drug
• Patients with permanent atrial fibrillation, or currently in persistent atrial fibrillation
• Patients with Type 1 diabetes
• Patients that have kidney failure and/or on dialysis
A randomized placebo-procedure controlled trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary artery denervation Safety and Efficacy in patients with combined pre- and post-capillary pulmonary hypertension associated with Left Heart Disease
A research study providing new treatment for pulmonary hypertension (high blood pressure in the arteries in the lungs) caused by left -sided heart disease. This study will evaluate the safety and effectiveness of investigational device called the Multi-Pole Pulmonary Artery Frequency Ablation Enhancor System ("Enhancor System").
Danielle Holmes - dholmes7@hfhs.org
• Subject is diagnosed with left sided heart failure for at least 6 months prior to being evaluated for the study and remains symptomatic despite an optimal medication regimen as prescribed by their treating physician(s).
• Patient's vital signs and internal heart pressures completed at screening and day of investigational procedure, prior to investigational implant, meet the study's inclusion requirements.
• . Subject is willing to follow all aspects of the research study, including medication compliance, follow--up visits, and testing.
• Subject has a life expectancy of less than 1 year due to non-cardiovascular causes.
• Subject has any severe heart valve disease.
• Subject has had a stroke or mini-stroke within 30 days prior to study enrollment.
• Subject refuses blood products.
• Subject has severe chronic kidney disease or on dialysis
• Subject has severe liver disease